Idera Pharmaceuticals reported $-5365000 in EBIT for its second fiscal quarter of 2022.


Ok
Trading Economics members can view, download and compare data from nearly 200 countries, including more than 20 million economic indicators, exchange rates, government bond yields, stock indexes and commodity prices.

The Trading Economics Application Programming Interface (API) provides direct access to our data. It allows API clients to download millions of rows of historical data, to query our real-time economic calendar, subscribe to updates and receive quotes for currencies, commodities, stocks and bonds.

Please Paste this Code in your Website
width
height
Ebit Change
Abbott ABT:US $ 2478M 434M
Agenus AGEN:US $ -44972000 8.98M
Alnylam Pharmaceuticals ALNY:US $ -191686000 44.95M
Amgen AMGN:US $ 2176M 324M
Biogen BIIB:US $ 940.9M 409.4M
Biomarin Pharmaceutical BMRN:US $ 39.15M 9.82M
Cytrx CYTR:US -1294610 692.11K
Dynavax Technologies DVAX:US $ 127.67M 96.2M
Eli Lilly And LLY:US $ 1650.5M 919.4M
Gilead Sciences GILD:US $ 2029M 868M
GlaxoSmithKline GSK:LN 1.82B 600M
Idera Pharmaceuticals IDRA:US $ -5365000 1.18M
Merk MRK:US $ 5711M 652M
Mirati Therapeutics MRTX:US $ -177205000 7.01M
Nektar Therapeutics NKTR:US $ -47713000 67.37M
Pfizer PFE:US $ 12099M 2104M
Sarepta Therapeutics SRPT:US $ -211132000 124.25M
Seattle Genetics SGEN:US $ -133111000 61K
Ultragenyx Pharmaceutical RARE:US $ -141593000 4.96M